Literature DB >> 17641065

Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction.

Michelle D'Souza1, Andrew P Fontenot, Doug G Mack, Catherine Lozupone, Stephanie Dillon, Amie Meditz, Cara C Wilson, Elizabeth Connick, Brent E Palmer.   

Abstract

Functional impairment of HIV-specific CD4(+) T cells during chronic HIV infection is closely linked to viral replication and thought to be due to T cell exhaustion. Programmed death 1 (PD-1) has been linked to T cell dysfunction in chronic viral infections, and blockade of the PD-1 pathway restores HIV-specific CD4(+) and CD8(+) T cell function in HIV infection. This study extends those findings by directly examining PD-1 expression on virus-specific CD4(+) T cells. To investigate the role of PD-1 in HIV-associated CD4(+) T cell dysfunction, we measured PD-1 expression on blood and lymph node T cells from HIV-infected subjects with chronic disease. PD-1 expression was significantly higher on IFN-gamma-producing HIV-specific CD4(+) T cells compared with total or CMV-specific CD4(+) T cells in untreated HIV-infected subjects (p = 0.0001 and p < 0.0001, respectively). PD-1 expression on HIV-specific CD4(+) T cells from subjects receiving antiretroviral therapy was significantly reduced (p = 0.007), and there was a direct correlation between PD-1 expression on HIV-specific CD4(+) T cells and plasma viral load (r = 0.71; p = 0.005). PD-1 expression was significantly higher on HIV-specific T cells in the lymph node, the main site of HIV replication, compared with those in the blood (p = 0.0078). Thus, PD-1 expression on HIV-specific CD4(+) T cells is driven by persistent HIV replication, providing a potential target for enhancing the functional capacity of HIV-specific CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641065     DOI: 10.4049/jimmunol.179.3.1979

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  129 in total

1.  Finding Balance: T cell Regulatory Receptor Expression during Aging.

Authors:  Mary M Cavanagh; Qian Qi; Cornelia M Weyand; Jörg J Goronzy
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

2.  Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in herpes simplex virus type 1-infected mice.

Authors:  Sariah J Allen; Kevin R Mott; Mandana Zandian; Homayon Ghiasi
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

3.  An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Authors:  Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

4.  Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease.

Authors:  Brent E Palmer; Douglas G Mack; Allison K Martin; May Gillespie; Margaret M Mroz; Lisa A Maier; Andrew P Fontenot
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

Review 5.  Animal models for viral infection and cell exhaustion.

Authors:  Colleen S McGary; Guido Silvestri; Mirko Paiardini
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

Review 6.  Distinctive features of CD4+ T cell dysfunction in chronic viral infections.

Authors:  Antigoni Morou; Brent E Palmer; Daniel E Kaufmann
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

7.  Responsiveness of HIV-specific CD4 T cells to PD-1 blockade.

Authors:  Filippos Porichis; Douglas S Kwon; Jennifer Zupkosky; Daniel P Tighe; Ashley McMullen; Mark A Brockman; David F Pavlik; Marta Rodriguez-Garcia; Florencia Pereyra; Gordon J Freeman; Daniel G Kavanagh; Daniel E Kaufmann
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

8.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Authors:  Cynthia L Gay; Ronald J Bosch; Justin Ritz; Jason M Hataye; Evgenia Aga; Randall L Tressler; Stephen W Mason; Carey K Hwang; Dennis M Grasela; Neelanjana Ray; Josh C Cyktor; John M Coffin; Edward P Acosta; Richard A Koup; John W Mellors; Joseph J Eron
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

9.  The natural killer cell interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects persist despite viral suppression.

Authors:  Stephanie M Dillon; Eric J Lee; Julia M Bramante; Edward Barker; Cara C Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

10.  The Distribution and Immune Profile of T Cell Subsets in HIV-Infected Children from Uganda.

Authors:  Isaac Ssewanyana; Chris A R Baker; Theodore Ruel; Stephanie Bousheri; Moses Kamya; Grant Dorsey; Philip J Rosenthal; Edwin Charlebois; Diane Havlir; Huyen Cao
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.